Suggested remit - To appraise the clinical and cost effectiveness of pembrolizumab with etoposide and a platinum-based compound within its marketing authorisation for untreated extensive-stage small-cell lung cancer
Following on from information provided to NICE by the company in July 2020 the appraisal of Pembrolizumab in combination for untreated extensive-stage small-cell lung cancer [ID1509] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1509
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 15 November 2022 | Note added to the project documents |
| 15 November 2022 | Discontinued. Following on from information provided to NICE by the company in July 2020 the appraisal of Pembrolizumab in combination for untreated extensive-stage small-cell lung cancer [ID1509] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 07 October 2020 | Committee meeting |
| 08 July 2020 | Suspended. Topic is suspended |
| 08 July 2020 | Note added to the project documents |
| 07 February 2020 | Note added to the project documents |
| 05 December 2019 - 10 January 2020 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 09 December 2019 | Note added to the project documents |
| 05 December 2019 | Note added to the project documents |
| 08 July 2019 | Note added to the project documents |
| 22 March 2019 | In progress. As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of pembrolizumab with chemotherapy for untreated extensive-stage small-cell lung cancer. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during mid- July 2019 when we will write to you about how you can get involved. |
| 14 November 2018 - 12 December 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 17 October 2018 | In progress. Topic referred |
For further information on our processes and methods, please see our CHTE processes and methods manual